

# Clinical trials of trandolapril

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>trandolapril vs placebo</b>			
<a href="#">TRACE , 1995</a> n=876/873 follow-up: 3 y	Trandolapril 1 mg daily initial dose, up to 4 mg daily versus placebo	patient within 37 days of a MI,Wall motion index <12 (LVEF <35% )	Parallel groups Double blind Denmark

More details and results :

- angiotensin-Converting Enzyme Inhibitors for acute myocardial infarction in patients with or without HF at <http://www.trialresultscenter.org/go-Q146>
- angiotensin-Converting Enzyme Inhibitors for acute myocardial infarction in patients with left ventricular dysfunction after MI at <http://www.trialresultscenter.org/go-Q147>

## References

### TRACE, 1995:

Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995 Dec 21;333:1670-6 [[7477219](#)]

## 2 heart failure

Trial	Treatments	Patients	Trials design and methods
<b>trandolapril vs placebo</b>			
<a href="#">TRACE , 1995</a> n=876/873 follow-up: 3 y	Trandolapril 1 mg daily initial dose, up to 4 mg daily versus placebo	patient within 37 days of a MI,Wall motion index <12 (LVEF <35% )	Parallel groups Double blind Denmark

continued...

Trial	Treatments	Patients	Trials design and methods
Hampton , 1998 n=144/148 follow-up: 16 weeks	trandolapril titrated up to 4mg/d versus placebo	patients with moderate (New York Heart Association Grades II and III) heart failure	double blind

More details and results :

- angiotensin-Converting Enzyme Inhibitors for heart failure in all type of heart failure at <http://www.trialresultscenter.org/go-Q43>
- angiotensin-Converting Enzyme Inhibitors for heart failure in MI patients with LV dysfunction without clinical evidence of HF at <http://www.trialresultscenter.org/go-Q238>

## References

### TRACE, 1995:

Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995 Dec 21;333:1670-6 [7477219]

### Hampton, 1998:

Hampton JR, Cowley AJ, Wnuk-Wojnar AM Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group. Eur Heart J 1998;19:1823-8 [9886725]

## 3 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
<b>trandolapril vs placebo</b>			
TRACE (AF ancillary study) , 1999 n=790/787 follow-up: 2.4 y	trandolapil versus placebo	Postmyocardial infarction	

More details and results :

- prevention for atrial fibrillation in patients without history of AF (primary prevention) at <http://www.trialresultscenter.org/go-Q331>

## References

### TRACE (AF ancillary study), 1999:

Pedersen OD, Bagger H, Kober L, Torp-Pedersen C Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. *Circulation* 1999;100:376-80 [[10421597](#)]

## 4 patients at high risk for cardiovascular events

Trial	Treatments	Patients	Trials design and methods
<b>trandolapril vs placebo</b>			
<b>PEACE , 2004</b> [NCT00000558] n=4158/4132 follow-up: median 4.8 y	Trandolapril at a target dose of 4 mg per day versus Placebo	patients with stable coronary artery disease and normal or slightly reduced left ventricular function	Parallel groups Double blind United States, Canada, Italy

More details and results :

- angiotensin-Converting Enzyme Inhibitors for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q98>
- inhibition of the renin-angiotensin system (ACEI or ARB) for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q157>

## References

### PEACE, 2004:

Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *N Engl J Med* 2004;351:2058-68 [[15531767](#)] [10.1056/NEJMoa042739](#)

Entry terms: trandolapril, Odrik, Udrik, RU 44570, RU44570, RU-44570, Mavik, Gopten